Koch's disease (Tuberculosis) - Symptoms, Causes, Treatment & Prevention

```html

Overview

Koch’s disease, more commonly known as tuberculosis (TB), is an infectious disease caused by the bacterium Mycobacterium tuberculosis. Although the lungs are the most frequent site of infection (pulmonary TB), the bacteria can spread to virtually any organ, producing extrapulmonary TB. TB remains a global public‑health challenge.

Who it affects: TB can affect anyone, but the highest burden is seen in:

• Adults aged 15‑44 years (the most socially and economically productive age group)
• People living with HIV/AIDS
• Individuals with diabetes, chronic kidney disease, or malignancy
• People in congregate settings (prisons, shelters, homeless populations)
• Undernourished or malnourished individuals

Prevalence: According to the World Health Organization (WHO), in 2023 there were an estimated 10.6 million new TB cases worldwide, resulting in 1.5 million deaths – the leading cause of death from a single infectious agent, surpassing HIV/AIDS. The United States reports roughly 8,000–9,000 new cases each year, with higher rates among foreign‑born persons and racial/ethnic minorities. [WHO Global TB Report 2024; CDC 2024]

Symptoms

TB symptoms vary by disease site and whether the infection is active (symptomatic) or latent (asymptomatic). Below is a complete list of common manifestations.

Pulmonary (Lung) TB

• Persistent cough lasting > 2 weeks, sometimes producing sputum that may be blood‑tinged.
• Chest pain – sharp or dull, often worsening with deep breaths.
• Fever – low‑grade, often in the evenings; may be accompanied by chills.
• Night sweats – soaking nightclothes and sheets.
• Unexplained weight loss – “wasting” despite adequate food intake.
• Fatigue and weakness – reduced exercise tolerance.

Extrapulmonary TB

• TB meningitis: severe headache, neck stiffness, altered mental status, photophobia.
• Spinal (Pott) disease: back pain, spinal deformity, neurological deficits.
• Lymph node TB (scrofula): painless, firm lymph node enlargement, usually in the neck.
• Genitourinary TB: dysuria, frequency, flank pain, hematuria.
• Peritoneal TB: abdominal pain, ascites, fever.
• Bone and joint TB: localized joint swelling, warmth, limited movement.
• Disseminated (miliary) TB: multisystemic symptoms – fever, chills, weight loss, respiratory distress.

Symptoms often develop slowly over weeks to months, which is why early medical evaluation is crucial.

Causes and Risk Factors

TB is caused by inhalation of aerosolized droplets from a person with active pulmonary TB. The bacteria are hardy, surviving in the environment for weeks under favorable conditions.

Primary Causes

• Airborne transmission – close, prolonged exposure in poorly ventilated spaces.
• Reactivation of latent infection when the immune system is weakened.
• Direct spread from an existing TB focus to other organs via the bloodstream or lymphatics.

Risk Factors

• Immunosuppression: HIV infection (TB is the leading cause of death among people with HIV), organ transplantation, corticosteroid therapy, biologic agents (e.g., TNF‑α inhibitors).
• Chronic diseases: diabetes mellitus (triples TB risk), chronic kidney disease, silicosis.
• Socio‑economic factors: poverty, homelessness, crowded housing, malnutrition.
• Substance use: tobacco smoking, alcohol misuse, illegal drug use.
• Travel or residence in high‑TB‑burden countries (India, Indonesia, Philippines, Pakistan, South Africa).
• Age: children <5 years and the elderly have higher susceptibility.

Diagnosis

Accurate diagnosis requires a combination of clinical assessment, radiographic imaging, and microbiologic testing.

1. Medical History & Physical Examination

Clinicians evaluate exposure history, symptom duration, risk factors, and perform a focused exam (lung auscultation, lymph node palpation, neurologic assessment when indicated).

2. Tuberculin Skin Test (TST) or Interferon‑γ Release Assays (IGRAs)

• TST (Mantoux test): intradermal injection of purified protein derivative; induration ≥10 mm (or ≥5 mm in high‑risk groups) after 48‑72 h suggests infection.
• IGRAs (e.g., QuantiFERON‑TB Gold, T‑SPOT): blood tests measuring interferon‑γ response to TB‑specific antigens; useful in BCG‑vaccinated individuals.

Both indicate infection (latent or active) but cannot differentiate disease activity.

3. Chest Radiography

Typical findings include apical infiltrates, cavitary lesions, hilar lymphadenopathy, or pleural effusion. However, a normal X‑ray does not exclude TB, especially early disease.

4. Microbiologic Confirmation

• Sputum smear microscopy: Ziehl‑Neelsen or fluorochrome staining for acid‑fast bacilli (AFB). Provides rapid, though less sensitive, results.
• Sputum culture (solid or liquid media): gold standard; yields definitive identification and drug‑susceptibility data, but takes 2‑8 weeks.
• Nucleic acid amplification tests (NAATs): e.g., Xpert MTB/RIF Ultra – detects TB DNA and rifampicin resistance within hours. Recommended by WHO as initial test for pulmonary TB.
• Extrapulmonary specimens: tissue biopsy, pleural fluid, cerebrospinal fluid, or urine, processed similarly.

5. Drug‑Susceptibility Testing (DST)

Essential for detecting multidrug‑resistant TB (MDR‑TB) and extensively drug‑resistant TB (XDR‑TB). Performed on cultured isolates or via molecular assays (e.g., line‑probe assays).

6. Additional Tests

• Complete blood count, liver function tests (baseline before therapy).
• HIV testing (mandatory per CDC guidelines).
• Blood glucose assessment in diabetics.

Treatment Options

Effective TB therapy requires prolonged multidrug regimens to eradicate slow‑growing mycobacteria and prevent resistance.

1. First‑Line Pharmacotherapy (Drug‑Sensitive TB)

Phase	Drugs (Typical Dosage)	Duration
Intensive (2 months)	Isoniazid (INH) 5 mg/kg daily Rifampin (RIF) 10 mg/kg daily Pyrazinamide (PZA) 15–30 mg/kg daily Ethambutol (EMB) 15–25 mg/kg daily	8 weeks
Continuation (4 months)	Isoniazid + Rifampin (same doses)	16 weeks

Adherence is critical; directly observed therapy (DOT) is recommended for many patients.

2. Treatment of Drug‑Resistant TB

• MDR‑TB (resistant to INH & RIF): 6–9 months of an intensive regimen including fluoroquinolone (e.g., levofloxacin), second‑line injectables (amikacin/kanamycin), and newer agents such as bedaquiline or delamanid.
• XDR‑TB (MDR‑TB + resistance to any fluoroquinolone and at least one injectable): individualized regimens based on DST, often lasting 18–24 months.

All regimens should be guided by an experienced TB specialist and closely monitored for toxicity.

3. Adjunctive Therapies

• Corticosteroids: indicated for TB meningitis and pericardial TB to reduce inflammation.
• Surgical intervention: required for persistent cavitary disease, drug‑resistant TB unresponsive to medical therapy, or spinal TB causing neurologic deficit.

4. Lifestyle & Supportive Measures

• Nutrition: high‑protein, calorie‑dense diet; vitamin D supplementation if deficient.
• Smoking cessation and alcohol reduction.
• Regular follow‑up labs to monitor hepatotoxicity and visual acuity (ethambutol).
• Adherence aids: pill boxes, mobile reminders, community health worker support.

Living with Koch’s disease (Tuberculosis)

Managing TB successfully involves medical treatment, self‑care, and social support.

Daily Management Tips

• Medication adherence: take meds on schedule, never skip doses; use DOT or video‑observed therapy if available.
• Monitor side effects: fever, rash, night vision changes (ethambutol), jaundice, or persistent nausea – report promptly.
• Infection control at home: keep windows open, use fans for ventilation, wear a surgical mask when around others during the first 2 weeks of treatment.
• Nutrition & hydration: aim for 2,200–2,500 kcal/day; include fruits, vegetables, lean protein; stay hydrated.
• Physical activity: gradual, low‑impact exercise (walking) improves stamina and lung function.
• Follow‑up appointments: sputum smears/cultures at 2‑month intervals until conversion, liver function tests monthly.
• Psychosocial health: TB can cause stigma; seek counseling, support groups, or community resources.

Work & School

Patients are usually non‑contagious after 2 weeks of effective therapy and negative sputum smears. Employers and schools should be informed of the need for temporary accommodation, but discrimination is unlawful.

Travel Considerations

Delay non‑essential travel until at least 2 weeks of treatment and documented sputum conversion. Carry a copy of the treatment plan and a letter from the treating physician.

Prevention

Because TB is preventable, public‑health measures focus on breaking transmission and treating latent infection.

Primary Prevention

• Vaccination: Bacillus Calmette‑Guérin (BCG) given to newborns in high‑burden countries; provides moderate protection against severe childhood TB.
• Infection‑control practices: adequate ventilation, ultraviolet germicidal irradiation in high‑risk settings, use of N95 respirators for healthcare workers.
• Screening of high‑risk groups: annual TST/IGRA for people with HIV, recent contacts of active TB cases, and healthcare personnel.

Latent TB Infection (LTBI) Treatment

Individuals with a positive TB infection test but no active disease are candidates for preventive therapy:

• Isoniazid 300 mg daily for 9 months.
• Rifampin 600 mg daily for 4 months.
• Weekly isoniazid‑rifapentine (3HP) for 12 weeks – preferred for better adherence.

LTBI treatment reduces the risk of progression to active disease by > 90 % (CDC 2023).

Complications

If TB is not promptly diagnosed and treated, serious complications may develop:

• Respiratory: permanent lung scarring, bronchiectasis, chronic obstructive pulmonary disease (COPD)-like picture.
• TB meningitis: hydrocephalus, seizures, long‑term neurologic deficits, death in up to 50 % of cases.
• Spinal TB (Pott disease): vertebral collapse, spinal cord compression, paralysis.
• Pericardial TB: constrictive pericarditis leading to heart failure.
• Disseminated (miliary) TB: multi‑organ failure, especially in immunocompromised hosts.
• Drug‑induced toxicity: hepatotoxicity, optic neuritis, peripheral neuropathy (if vitamin B6 not supplemented).

When to Seek Emergency Care

Sources: World Health Organization. Global Tuberculosis Report 2024; CDC. Tuberculosis – Fact Sheets; Mayo Clinic. Tuberculosis (TB) Overview; NIH National Institute of Allergy and Infectious Diseases; Cleveland Clinic. Tuberculosis Treatment; The Lancet Respiratory Medicine. 2023; WHO. TB preventive treatment guidelines 2023.

```